UBS Maintains Buy on DexCom, Lowers Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $175 to $138.

September 06, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS maintains a Buy rating on DexCom but lowers the price target from $175 to $138, which may impact the stock's short-term performance.
The news is directly related to DexCom and is likely to influence investor sentiment. While the maintained Buy rating is positive, the lowered price target might create some uncertainty, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100